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Figures and Tables from manuscript  
 
Figure 1: Proportion of germline pathogenic variants from hereditary Breast and Ovarian 
cancer patients that are large genomic re-arrangements. (LGR: large genomic rearrangement, 
SNV: single nucleotide variant, Indel: insertion or deletion) 
 
 
Page 2 of 36
https://mc.manuscriptcentral.com/ijgcancer
International Journal of Gynecological Cancer
Confidential: For Review Only
Tumour BRCA (tBRCA) guidelines for pathologists are extrapolated from 
recommendations for HER-2 testing. There are no published studies on pathology 
protocols and result outcomes in tBRCA testing. This guidance is based on general 
principles and author experience.  
Tubo-ovarian cancer and BRCA 
The frequency of BRCA1 and BRCA2 germ-line pathogenic variations (mutations) in 
women with tubo-ovarian cancer is variably quoted. If all tubo-ovarian cancers are 
taken into consideration, the stated frequency is 10 – 15%.  [Alsop K, Fereday S, 
Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, 
Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency 
and patterns of treatment response in BRCA mutation-positive women with ovarian 
cancer: a report rom the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 
Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545.]. When somatic mutations 
are included, this figure rises to 20% or greater. [Ledermann JA, Drew Y, Kristeleit 
RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 
2016;60:49-58. doi:10.1016/j.ejca.2016.03.005].  
Recombinant DNA Repair 
Recombination occurs when two molecules of DNA exchange pieces of genetic 
material with each other. This must be accurate in order to maintain genetic integrity. 
The most notable example of recombination is in meiosis resulting in creation of 
gametes that contain new combinations of parental genes. Throughout life, the DNA 
undergoes damage. There are six major DNA repair pathways in humans. These 
include base excision repair, nucleotide excision repair, single strand break repair, 
homologous recombination (HR) repair, non-homologous end joining and mismatch 
repair. [Jackson SP, Bartek J. The DNA-damage response in human biology and 
disease. Nature. 2009;461(7267):1071-1078. doi:10.1038/nature 08467]. The HR 
pathway consist of a set of related sub-pathways that utilize DNA strand invasion 
and template-directed DNA repair synthesis to effect a high-fidelity repair of 
damaged DNA. 
Recombinant DNA repair and BRCA pathogenic variants 
The HR pathway involves the coordinated interactions of many proteins including 
BRCA1 and BRCA2 and other proteins such as RAD51 and proteins of the Fanconi 
anaemia pathway. Alterations of the BRCA1 and BRCA2 genes may occur as a 
germline abnormality, but may also occur through mechanisms such as somatic 
mutations and epigenetic silencing. [Moschetta M, George A, Kaye SB, Banerjee S. 
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian 
cancer. Ann Oncol. 2016;27(8):1449-1455.] Deficiency in HR is a target for 
Poly(ADP-ribose) polymerase (PARP) inhibitors. 
Germline mutations vs somatic mutations 
Germline mutations are inherited mutations and are present in every cell of the body. 
Somatic mutations are non-inheritable mutations that are found only in tumour cells. 
Upto 6-7% of high grade serous tubo-ovarian carcinomas have somatic BRCA1/2 
mutations. tBRCA and somatic BRCA are not synonymous. BRCA mutations in 
tumour cells reflects both germline and somatic mutations.  
Testing for BRCA pathogenic variants (mutations) 
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Germline testing is generally done using blood. tBRCA testing is done mostly by 
using formalin fixed paraffin embedded (FFPE) tissue from the carcinoma. Cytology 
samples, rarely, can also be used. 
Reasons for tBRCA testing 
PARP inhibitors inhibit DNA repair pathways and cause apoptosis/death of cancer 
cells, especially in HR-deficient cells. tBRCA testing is important to identify this 
subgroup of patients. Tumours harbouring BRCA1/2 mutations (detected by tBRCA 
testing) in the tumour, irrespective of germline or somatic, are also associated with 
better resp nse to platinum-based chemotherapy. tBRCA abnormalities due to 
germline BRCA mutations have additional implications in identifying BRCA germline 
mutation carriers. 
Role of the pathologist 
The pathologist plays an important role in selection of the test sample and is the 
member of the multidisciplinary team who has access to pre-test and post-test 
pathways and is pivotal in establishing standard operating procedures, audit of the 
process and institution of change if needed. 
Understanding pre-analytic variables 
The process of acquiring tissue starts with tissue collection by the clinician as a 
diagnostic or resection sample. Warm ischemia time is the time from the interruption 
of the blood supply to the tumour to the excision of the tissue specimen. This is 
followed the cold ischaemia time which is the time taken to transfer the surgical 
specimen into the fixative. The length of this time influences the levels of gene 
expression and is an important factor. The cold ischaemia time is less for small 
samples acquired at inpatient or outpatient settings.  
Once in the specimen container, the tissue is penetrated by the fixative before the 
actual process of fixation starts. This is a problem particularly with large specimens 
such as ovarian tumours. [Goldstein NS Hewitt SM, Taylor CR, Yaziji H, Hicks DG 
Recommendations for Improved Standardization of Immunohistochemistry.” Applied 
Immunohistochemistry & Molecular Morphology 15 (2007): 124-133]. 
The fixative of choice is 10% neutral buffered formalin. Formalin should only be used 
for upto 24 h after dilution to 4% w/v. After 24 hours, polymerisation starts and a 
stable ph and 4% concentration gets affected. Formalin penetrates tissue at around 
1 mm/hour.  A minimum of 6 hours of formalin fixation is required, complete tissue 
fixation requires up to 24 hours. Prolonged fixation (arbitrarily designated as beyond 
36 hours) is a possible cause for test failure and should be averted wherever 
possible. Fixation over the weekend, especially of small biopsies, should be avoided.  
Laboratory processes 
Sections should be cut under conditions (clean microtome etc) that avoid cross 
contamination from other specimens. 
Appropriate numbers of air dried, mounted, unstained, non coverslipped sections 
should be sent. 
For cytology specimens, It is essential that cells and tissue fragments from the 
cytology samples are processed into agar/cell blocks, formalin-fixed and paraffin 
embedded and then undergo an assessment process as per tissue samples.  
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The request forms 
Requests for tBRCA testing can be made by managing clinicians, nurse specialists, 
multidisciplinary teams or pathologists. This is a local decision.  In all scenarios, 
patient consent needs to confirmed and documented.   
At the time of writing these guidelines, the BRCA form testing form (Astra Zeneca) 
can be downloaded from  
https://medicines.astrazeneca.co.uk/content/dam/multibrand/uk/en/resources/lynparz
a/tbrca-testing/0715-test-request-form-Manchester.pdf   
https://medicines.astrazeneca.co.uk/content/dam/multibrand/uk/en/resources/lynparz
a/tbrca-testing/0715-test-request-form-Royal-Marsden.pdf  
The results should be requested to generic pathology and generic clinical emails.  
Choosing material for testing 
In England, tBRCA testing is advised for high grade serous carcinomas and in 
Scotland tBRCA testing is advised for high grade serous and endometrioid 
carcinomas. The diagnosis is made in several settings. The pathologist or advanced 
practitioner dealing with the specimen may not be a specialist in gynaecological 
pathology. This guideline advises the following in order to conserve the maximum 
amount of tissue for tBRCA test. 
Biopsy of suspected tuboovarian carcinoma:  
·            Cores blocked separately (at least 2 blocks)  
·            H&E on both blocks to confirm cancer  
·            One block (preferably the one with less tissue/tumour) for confirmatory IHC  
·            IHC to confirm high grade serous carcinoma (PAX8+ve, WT1 +ve, ER +ve. 
p53 mutation/aberrant)  (https://www.thebagp.org/download/bagp-ukneqas-project-
p53-interpretation-guide-2016/) If there is diagnostic uncertainty, in order to preserve 
tissue for testing, further immunostains should not be done. The available material 
should be sent to Cancer Centre for review and diagnosis. 
·            Tissue/blocks, H&E and immunostained slides should be sent to nominated 
pathologist. 
Resection specimen from known high grade tuboovarian serous carcinoma:  
·            Reporting pathologist should send block/tissue from primary or metastatic 
carcinoma containing maximum viable and well-fixed tumour and its H&E stained 
slide to nominated pathologist   
Cell block from fluid sample (pleural effusion or ascites) in suspected tuboovarian 
carcinoma: 
·            H&E to confirm cancer  
·            Minimal IHC to confirm high grade serous carcinoma (PAX8+ve, WT1 +ve, 
ER +ve. p53 mutation/aberrant)   
·            Block, H&E and IHC slides sent to nominated pathologist. 
Sending material for testing 
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Nominated pathologist/s mark tumour areas on H&E slide and estimates tumour 
volume within the whole section and within the marked areas. As a guidance, the 
marked areas should contain at least 20% tumour cells. 
  
The tissue block, the marked slide and the completed form are sent to the 
appropriate genetic laboratory hub. 
Recording the report 
When the result is received, it should be added (in full) to the initial pathology report 
as a supplementary. Wherever possible, the pathologist should enable including the 
result in the MDT and patient records and make the result accessible to the 
managing clinician. Local pathways should be followed 
Audit 
We recommend that there should be mechanisms in place to document preanalytic 
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Receiving a BRCA1 and BRCA2 test result that identifies an alteration 
 
Information sheet for patients with cancer 
 
You had a BRCA1 and BRCA2 gene test because of your diagnosis of cancer.  
 
The test result has shown that you have a pathogenic variant (alteration) in either 
the BRCA1 or BRCA2 gene. This was found in your cancer sample as well as your 
blood sample.  
  
BRCA1 or BRCA2 alterations result in increased risks of breast, ovarian and prostate 
cancer, and occasionally other cancers. Therefore, this result provides an explanation for 
why you developed cancer.  
 
This result has implications for your future health and potentially for your relatives. A 
referral has been made for you to the Clinical Genetics team discuss these issues further.  
 
At your Genetics appointment you will be able discuss your future risks of cancer and your 
options for cancer screening and measures to reduce the risk of cancer. The potential 
implications for relatives will also be discussed. The processes by which your relatives can 
be referred themselves to decide if they wish to have testing will be explained.  
 
If you have not heard from the Genetics team with an appointment date in the next 4 
weeks, please contact them on 0117 342 5107 to check the progress of your referral.  
 
Your cancer team will discuss with you if this result has implications for your cancer 
treatment and/or follow-up. 
 
If you have any further questions in relation to your ongoing cancer treatment, please 
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Receiving a BRCA1 and BRCA2 test result that identifies an alteration in your 
cancer 
 
Information sheet for patients with cancer 
 
You had a BRCA1 and BRCA2 gene test because of your diagnosis of cancer.  
 
The test result has shown that you have a pathogenic variant (alteration) in either 
the BRCA1 or BRCA2 gene in your cancer sample. This alteration was not found in 
your blood sample.  
 
What does this result mean for me? 
Your cancer team will discuss with you if this result has implications for your cancer 
treatment and/or follow-up. Because this alteration was not found in your blood sample, it 
does not have implications for your risks of other cancers.  
 
If you have a strong family history of breast and/or ovarian cancer, or a strong family 
history of other cancers, or if you developed cancer at an unusually young age, it may be 
helpful to look into things further. The cancer team will discuss this with you and, if 
appropriate, refer you for further assessment by the Clinical Genetics team. 
 
Very occasionally alterations in other genes can be involved in causing breast or ovarian 
cancer. Also new discoveries are being made all the time.  In the years to come if you 
would like to find out if any further genetic testing is available, please discuss this with your 
GP, who could refer you to the genetics team, if appropriate. 
 
What does this result mean for my relatives? 
This result is good news for your relatives, as it means they are less likely to be at a high 
increased risk of developing breast and/or ovarian cancer themselves because it was not 
found in your blood sample. You may wish to share this result with them.  
 
There is currently no known effective form of ovarian screening. If a woman has more than 
one relative with ovarian cancer, removal of the ovaries is sometimes considered.   
All women are eligible to have mammograms from 47 years in the National Breast 
Screening Programme. Depending on the family history, some women may be eligible for 
mammograms from 40 years.  
If this is the case in your family, please discuss this further with your cancer team. 
 
If any of your relatives wish to discuss their own risks of cancer further, they should speak 
with their GP who can refer them for further discussions at their local Family History 
screening clinic. 
 
If you have any further questions, please contact your cancer team on [local contact 
details].  
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What are cancer-causing genetic variants called? 
Many different words are used to describe cancer-
causing genetic changes. “Mutation,” “disease-causing 
alteration or variant,” “pathogenic mutation,” or 
“pathogenic variant” are all terms you may come 
across. We will use the term “pathogenic variant” to 
describe a variant in a gene which is known to cause 
cancer. 
You have been given this leaflet because you have been 
diagnosed with ovarian cancer. Genetic testing of your 
tumour will help your oncologist plan the best 
treatment for you. Genetic testing of your blood may 
help guide your future care and provide you with 
information on future cancer risk. It may also give us 
information to help your relatives to manage their 
future cancer risk.   
 
Cancer is a common condition which will affect up to 1 
in 2 people in the general population in their lifetime.  
In the UK around 2 in 100 (2%) women develop ovarian 
cancer. The majority (85 out of 100, or 85%) of ovarian 
cancer cases are due to a combination of increasing 
age, environmental, lifestyle, and low risk genetic 
factors.  
 
Cancer in the general population 
 
  Why am I being offered a genetic test? 
What are genes? 
Genes are our cells’ instruction manuals.  We each have 
around 20,000 pairs of genes which are present in 
almost every single cell of our bodies.  Our genes tell 
our cells how to function normally.  Different genes 
have different roles in the body. The genetic test we are 
offering you looks to see if there are changes in two 
genes associated with ovarian cancer. 
 
Which genes are associated with ovarian cancer? 
 
The two main genes we test for in ovarian cancer are 
called BRCA1 and BRCA2. We all have two copies of 
these genes, as we inherit one copy from each of our 
parents. We can look at the BRCA1 and BRCA2 genes in 
the ovarian cancer cells (the tumour) to see if there is a 
somatic pathogenic variant. To see if this variant is also 
present in other cells in the body we can also look at the 
BRCA1 and BRCA2 genes in the blood cells. If the variant 
is also present in the blood cells this means it is an 
inherited germline pathogenic variant.  
   
Genetic Testing of BRCA1 and BRCA2 in a 
person with ovarian cancer  
 
1.  Somatic testing (from your tumour) 
 
a) A BRCA1 or BRCA2 pathogenic variant is detected in 
your tumour sample which we know is associated with 
ovarian cancer. Your oncologist may use this 
information to guide your treatment. We would need 
to check to see if the variant is also present in your 
blood sample. 
 
b) No BRCA1 or BRCA2 pathogenic variant is detected 
in your tumour sample. In this case it would be unlikely 
that your cancer was caused by a BRCA pathogenic 
variant. We would still check your blood test results to 
confirm this.  
 
What are the outcomes of testing? (1) 
 
How do changes in genes cause cancer? 
 
Most of the time cancer-causing genetic changes are 
found ONLY in the cancer cells (in the tumour). In this 
case the changes are called “somatic pathogenic 
variants”.  
 
A smaller number of women with ovarian cancer have 
inherited a genetic change which means they are more 
at risk of cancer. This is a called a “constitutional or 
germline pathogenic variant”. 
 
How do we test for genetic variants? 
 
There are two tests to look for genetic changes that 
may have contributed to you developing cancer. 
 
1. Tumour testing to look for somatic variants. Your 
oncologist will send a sample of your tumour onto a 
specialist laboratory to test it for variants in BRCA1 and 
BRCA2. These results will take around 5 weeks to be 
reported. 
 
2. A blood test to look for germline variants. Your 
treating team will take a blood sample from you and 
ask you to sign a consent form to have this sample 
stored. A member of the genetics team will contact 
you to explain more about testing your blood sample 
for variants in BRCA1 and BRCA2. The results may take 
around 6-8 weeks to be reported.   
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Websites for further Information 




Ovarian symptoms (Ovarian Cancer National Alliance): 
http://www.ovariancancer.org/about-ovarian-
cancer/symptoms/     
Details regarding your test 
• Date of test: 
 
• Contact person: 
  
• Results expected:  
     
To provide feedback on this leaflet please go to 
https://www.surveymonkey.co.uk/r/DHX7HQN 
What are the outcomes of testing? (2) 
 
1. Germline testing (from your blood sample) 
 
(a) A BRCA1 or BRCA2 pathogenic variant is detected in 
your blood sample which we know is associated with 
ovarian cancer. This is often called being a “BRCA 
carrier.” This will likely explain why you developed 
cancer. 
 
In this case you would meet with a member of the 
genetics team to discuss what this means for your 
future management and for your relatives. We know 
that germline BRCA carriers are at increased risk of 
breast cancer as well as ovarian cancer. Although 
treating your ovarian cancer takes priority, we can also 
assess your future breast cancer risk and offer 
personally tailored advice about managing this risk.  
 
The chance that a first degree relative 
(parent/sibling/child) of a person with a pathogenic 
variant will also carry that variant is 1 in 2 (50%). We 
can support families to share this information with 
relatives so they can be tested. 
 
(b) No BRCA1 or BRCA2 pathogenic variant is detected 
in your blood sample. In this case it would be less likely 
that your cancer was due to an inherited condition. You 
will still have a full review of your personal and family 
history to check no further genetic testing or screening 
is needed. 
 
(c) A Variant of Uncertain Significance is detected (VUS). 
In rare cases we may identify a BRCA1 or BRCA2 variant, 
but we do not know if it is affecting the way the gene is 
working to cause cancer.  This is known as a ‘variant of 
unknown significance.’ Most of these are likely to be 
harmless and we would usually manage you as if you 
had no variant identified. Sometimes we may wish to 
perform additional tests to clarify the significance of the 
variant which we will discuss with you. As our 
knowledge about genetic variation increases, we may 
decide this variant is pathogenic or harmless and 
change your management if needed. 
 
Your oncologist may use this information to help 
decide the best treatment for your cancer. In 
particular, they may suggest prescribing a medication 
called a PARP Inhibitor. PARP Inhibitors have been 
shown to improve response to cancer treatment in 
BRCA carriers.  
 
How will finding a pathogenic variant in BRCA1 or 
BRCA2 affect my treatment? 
 
If you do not have either tumour or blood testing, your 
oncologist will not be able to use the test information 
in your treatment plan and Genetics would make a risk 
assessment for family members based on the family 
history alone. 
 
Sometimes, although someone does not wish to 
pursue a blood test at that time, they may decide to 
have a blood sample stored for either their own future 
use or for that of their family members.  This is 
something we can discuss with you.  You could still 
have your tumour tested to help make decisions about 
your treatment if you wish.  
 
What can be done if I decide not to undergo 
testing? 
 
The genetics team will take a family history to make 
sure we have offered you all the tests you need. They 
will also use this information to give screening advice 
in the family, even if a genetic test is negative. You can 
fill out your family history information in advance of 
your appointment at www.fhqs.org or by scanning the 
QR code below. 
 
Family history information 
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43 The British Gynaecological Cancer Society and the British Association of 
44 Gynaecological Pathologists established a multidisciplinary consensus group 
45 comprising experts in surgical gynaecological oncology, medical oncology, genetics, 
46 laboratory science and clinical nurse specialists to identify the optimal pathways to 
47 BRCA germline and tumour testing in patients with ovarian cancer in routine clinical 
48 practice. In particular, the group explored models of consent, quality standards 
49 identified at pathology, laboratory and experience/data from pioneering cancer 
50 centres. The group liaised with representatives from ovarian cancer charities to also 
51 identify patient perspectives that would be important to implementation. 
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58 Pathogenic germline BRCA1/2 variants play a key role in the etiology of epithelial 
59 ovarian cancer. Recent studies showing the prevalence of pathogenic BRCA 
60 germline mutations in patients with high-grade serous ovarian cancer of 13-15% as 
61 well as the recognition of the clinically significant role of therapeutic poly-ADP ribose 
62 polymerase (PARP) inhibition in BRCA deficient tumours has led to an expansion in 
63 demand for germline BRCA testing.1-6 The Cancer Genome Atlas (TCGA) identified 
64 somatic and germline BRCA pathogenic variants in ~22% of high-grade serous 
65 ovarian cancers.7  
66 To manage this increased demand and ensure timely access to testing early on in 
67 the patient care pathway, models of delivery using surgeons, oncologists or clinical 
68 nurse specialists to “mainstream” germline testing have been developed in many 
69 centres. In these models, cancer clinicians counsel and offer germline BRCA testing 
70 to all ovarian cancer patients and only patients with pathogenic variants or variants 
71 of uncertain significant are referred to genetics services.
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72 Different models have developed across the UK with variable testing criteria, 
73 availability and access.4, 8, 9 Some models restrict testing to defined histological 
74 criteria (high-grade serous or endometrioid), others restrict testing to age groups 
75 (under 70 years). However, there is considerable variability in implementation of 
76 mainstream germline BRCA testing worldwide with some centres still relying on 
77 individual clinicians referring patients to regional genetics centres and approximately 
78 30% of eligible patients not being offered testing.10
79
80 Until 2018, the evidence base for maintenance PARP inhibition strategies was 
81 restricted to women with relapsed ovarian cancer. However, following publication of 
82 the SOLO-1 trial, the evidence for benefit has been demonstrated in the first-line 
83 setting with women with BRCA-deficient advanced stage IIIC/IV ovarian cancer 
84 having significantly longer progression-free survival with mai tenance olaparib 
85 compared to placebo.11 
86
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87 There are currently two methods by which BRCA testing may be undertaken, each of 
88 which detects slightly different pathogenic variants due to the pathogenesis of the 
89 mutations and the limitations of the analytical techniques.  Germline testing is 
90 undertaken on blood samples and will detect inherited pathogenic variants, including 
91 the large duplications/deletions which are not reliably detectable on tumour testing. 
92 Thus, germline testing results carries implications for family members. Tumour 
93 testing involves extracting DNA from the ovarian tumour and subjected to test for 
94 pathogenic variants. Approximately two-thirds of the mutations detected in tumour 
95 will be of germline (inherited) origin, however nearly one-third will be found to be 
96 somatic (tumour only – not inherited) mutations. Therefore, tumour testing results 
97 may have implications for family members in some, but not all instances. 
98 Crucially, PARP inhibition increases progression-free survival in patients with 
99 somatic BRCA mutation.11 Therefore, patients and clinicians need as much 
100 information as possible to guide treatment choices in the first-line setting. 
101 Thus, there is an urgent clinical need to clearly identify women whose tumours 
102 contain deleterious BRCA mutations early in their ovarian cancer treatment journey 
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103 to maximize the population of women afforded the opportunity of PARP inhibitor 
104 treatment upon completion of first-line chemotherapy. Additionally, unselected 
105 germline testing identifies approximately 50% more women whose families may 
106 benefit from predictive testing and subsequent screening and prevention in 
107 unaffected individuals.12 
108 Implementing these tests into routine practice at first-line treatment of ovarian cancer 
109 requires careful consideration of issues around scheduling of both tests, the timing of 
110 testing in relation to first-line therapy, counselling of patients, costs involved, sample 
111 management processes, quality controls and audit trails.  This guidance document 
112 evaluates the underlying evidence and sets out recommendations for implementation 
113 into clinical practice in the United Kingdom. 
114 Detection of different DNA variants in germline testing
115 Next generation sequencing based technologies are used for detection of BRCA 
116 ‘point mutations’ (single nucleotide variants or small insertion/deletion variants 
117 typically <40 bp in size) in both blood (germline) and tumour samples. Although 
118 pathogenic large genomic rearrangements can be detected in germline samples 
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119 using next generation sequencing, the algorithms show reduced sensitivity for 
120 smaller, single exon large genomic rearrangements. Consequently, pathogenic large 
121 genomic rearrangements in BRCA are typically detected in clinical laboratories using 
122 multiplex ligation dependent probe amplification in blood samples. However, 
123 multiplex ligation dependent probe amplification has a high analytical failure rate in 
124 formalin fixed paraffin embedded derived tumour DNA due to poor DNA quality and 
125 genomic instability present in many ovarian tumours and is consequently not 
126 routinely employed. 
127 Scheduling of germline and tumour BRCA testing
128 The consensus group carefully reviewed the emerging evidence summarised below 
129 to formulate its recommendation on scheduling of testing.
130 Evidence from the SIGNPOST study 
131 A concomitant/parallel panel germline and tumour genetic testing pathway for all 
132 high-grade non-mucinous epithelial ovarian cancer was initially introduced at Barts 
133 Health (North East London Cancer Network) in 2016. This involved an initial period 
134 of training of clinical staff (surgeons, medical oncologists, clinical nurse specialists, 
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135 design of patient information materials and was undertaken within the SIGNPOST 
136 (SystematIc GeNetic Testing for Personalised Ovarian Cancer Therapy) study 
137 (ISRCTN 16988857). Germline testing included testing for BRCA1, BRCA2, 
138 RAD51C, RAD51D, BRIP1. Tumour testing was undertaken for BRCA1 and BRCA2 
139 genes. Both germline and tumour testing were done in parallel. This was offered 
140 both prospectively and retrospectively to those with a pre-existing diagnosis.
141 Pathogenic variant rates identified in the SIGNPOST study were consistent with what 
142 has been previously reported in the literature. Critically, this study shows that 10% of 
143 BRCA mutation carriers (those individuals with large genomic rearrangements) 
144 would not have been identified without concomitant parallel testing for both germline 
145 and somatic mutations (personal communication Prof Manchanda, unpublished 
146 data).
147 Evidence from Imperial College Healthcare NHS Trust and the Royal Marsden 
148 Hospital
149 At Imperial College Healthcare NHS Trust, parallel germline and tumour BRCA 
150 genetic testing is offered to all eligible ovarian cancer patients.   The cancer team 
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151 discuss the pathways and possibility of genetic testing and its implications with the 
152 patient at initial presentation. If consent is obtained, germline and tumour tests are 
153 requested from the gynaecological oncology clinic.
154 The Royal Marsden Hospital initiated mainstream germline BRCA testing in 2012 for 
155 all patients with non-mucinous ovarian cancer through the oncology teams as 
156 standard of care.  Subsequently, reflex tumour testing was introduced for all patients 
157 with high-grade serous ovarian cancer. Currently, the data (unpublished) from The 
158 Royal Marsden Hospital has identified 9% of patients with pathogenic variants 
159 present only in the tumour; and 15% of patients with germline pathogenic variants 
160 that were not detected in the tumour testing. All of the latter represent large genomic 
161 rearrangements (duplications or deletions) that are not reliably detectable during 
162 tumour BRCA testing due to DNA fragmentation. 
163 Evidence from Public Health England 
164 Data from Public Health England shows that as of end of February 2020, from a total 
165 of 17,384 pathogenic BRCA variants reported by all labs in England, 1,830 were 
166 large genomic rearrangements.  (Personal communication from Fiona McRonald, 
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167 Programme Manager, Molecular, Genomic and Research Data National Disease 
168 Registration, Public Health England). See Figure -1. However, it is widely accepted 
169 in England, that there are several ‘hotspots’ for large genomic rearrangements, 
170 which also coincide with less access to testing, thus, the true proportion of large 
171 genomic rearrangements in this population may be closer to 15-17% of pathogenic 
172 variants. This would be consistent with data from the Manchester and Royal 
173 Marsden labs (unpublished). 
174
175 In England, given above results, a parallel testing would be the most effective 
176 strategy and would avoid missing a proportion of patients (roughly 10%), as tumour 
177 testing alone using ‘next generation sequencing’ technology is likely to miss the 
178 proportion of patients with germline pathogenic large genomic rearrangements of 
179 BRCA. Conversely, germline testing alone will miss a proportion of patients with only 
180 somatic variants in BRCA. Ongoing studies in Scotland will provide information for 
181 local populations.
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182 Each health system will need to establish baseline rates to determine whether 
183 sequential testing or parallel testing is optimal for their patient groups. In patients 
184 with limited ethnicity specific data such as those from South Asian populations 
185 (https://academic.oup.com/pcm/article/1/2/75/5106037), parallel testing will be 
186 particularly important.  
187 Timing of BRCA testing in relation to first-line treatment 
188 The consensus group reflected on two issues in this section; the first to preserve 
189 patient choice and autonomy in making an informed decision, the second the crucial 
190 utility of knowledge of BRCA status in decisions for 
191 neoadjuvant/adjuvant/maintenance treatments at first-line settings. The consensus 
192 group also had discussions with ovarian cancer charities representing patient 
193 perspectives.  The consensus group agreed that preserving patient choice in timing 
194 of testing was key. However, discussions around BRCA testing should start at the 
195 earliest available opportunity in a patient’s cancer diagnosis journey.
196 In the ideal scenario, earliest testing at the time of diagnosis of ovarian cancer is vital 
197 so that BRCA status is available when it is clinically most relevant to the patient and 
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198 should factor in the local turnaround time for testing and the potential need for 
199 genetic counselling. It is recognized that patients may feel ready to undergo testing 
200 at different points in their cancer journey. The counselling and consenting can be 
201 carried out by a trained gynaecological oncologist, the referring gynaecologist with 
202 expertise in gynaecological oncology (cancer unit lead in the UK), oncologist or 
203 adequately trained clinicians (Clinical Nurse Specialist). Some patients may need to 
204 access the genetics service for pre-test counselling and this should be supported 
205 where possible. 
206 Initial consultation
207 BRCA tumour testing can be discussed with patients who present with a high clinical 
208 suspicion of ovarian cancer (carcinomatosis on CT (computerized tomography) scan 
209 with CA125/CEA ratio >25) at initial presentation to a referring gynaecologist (cancer 
210 unit lead in the UK) or gynaecological oncologist, prior to confirmatory histological or 
211 cytological diagnosis. 
212 Consultation before primary cytoreductive surgery 
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213 As part of the counselling and consenting for primary cytoreductive surgery, informed 
214 consent should be sought for tumour BRCA mutation testing; this can be in the form 
215 of a verbal discussion which is documented. Although undertaken by some centres 
216 (and considered good practice), currently tumour testing does not necessitate written 
217 consent in the UK.  Information on whether the patient has provided or declined 
218 consent for tumour testing should be communicated with the pathology team 
219 receiving the surgical specimens after primary cytoreductive surgery, by being 
220 recorded in the pathology request form or communicated via other means. This will 
221 enable a streamlined process wherein the pathology team can identify the 
222 representative tumour block (or slides) and arrange transfer of the specimen to the 
223 genomic laboratory hub once a diagnosis of high-grade serous carcinoma or high-
224 grade endometrioid cancer of tubo-ovarian or peritoneal origin is confirmed. 
225 Consultation after primary cytoreductive surgery 
226 If the pathology of the surgery reveals non-mucinous high-grade epithelial ovarian 
227 cancer, the patient should be counselled about germline BRCA mutation testing and 
228 written consent must be obtained. If consenting for tumour BRCA mutation testing 
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229 was not obtained prior to surgery, this should be done and the nominated pathologist 
230 should be informed. 
231 Consultation before biopsy in patients planned to receive neoadjuvant 
232 chemotherapy: 
233 If the patient is not suitable for primary cytoreductive surgery (or in cases of 
234 diagnostic uncertainty) counselling about tumour BRCA testing should be performed 
235 before the imaging-guided biopsy or diagnostic laparoscopy.  Informed consent 
236 should be obtained either in the form of a verbal discussion which is documented or 
237 through a formal consent form. The fact whether the patient has provided or declined 
238 consent for tumour testing should be recorded in the pathology request form after 




243 In order to obtain adequate amount of chemotherapy naïve tissue, extra cores of 
244 tumour tissue should be obtained for the purpose of successful tumour BRCA 
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245 mutation testing. This must be recorded in the histopathology request form. 
246 Experience from the BRITROC study suggests that image guided biopsy using an 
247 18-gauge needle and two passes are feasible and acceptable to patients and results 
248 in adequate tissue sampling.13 If the pre-chemotherapy biopsy does not yield 
249 adequate tissue sample for BRCA testing, tumour testing should be reconsidered 
250 from the interval debulking surgery specimens in patients with negative germline 
251 testing. As the success rate of tumour sequencing from post chemotherapy 
252 specimens is lower (impaired DNA yield) compared to chemotherapy naïve tissue, 
253 maximum attempt should be made to obtain adequate amount of tissue during pre-
254 treatment biopsy. If debulking surgery is not performed after neoadjuvant 
255 chemotherapy, repeat imaging-guided biopsy for tumour testing should be 
256 considered.    
257 Diagnostic laparoscopy
258 Adequate biopsy should be taken to provide the genetic laboratories with a sufficient 
259 amount of tissue for tumour testing.
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260 Ascites cytology (in rare cases where tissue cannot be obtained)
261 Ascitic fluid should be sent to the pathology laboratory to obtain a tumour cell-rich 
262 block. A summary of indications, timing, sequence of testing and consent process is 
263 summarised in Table 1. 
264 Pathology - Tissue handling and pathways for tumour BRCA testing 
265 The mutation testing relies on detecting a mutant allele in a background of wild type 
266 alleles. It is important that adequate numbers of malignant cells are available to 
267 provide DNA for the test. Therefore, maximising the tissue available in a diagnostic 
268 biopsy is of paramount importance. Any biopsy done with suspicion of tubo-ovarian 
269 cancer must be sampled in at least two blocks. One block (with the lesser volume of 
270 tumour) should have an H&E (hematoxylin and eosin) stain with a confirmatory panel 
271 of PAX8, WT1, ER and p53. In context of morphology, PAX8 +ve, WT1 +ve, ER +ve 
272 and p53 mutation/aberrant staining (https://www.thebagp.org/download/bagp-ukneqas-
273 project-p53-interpretation-guide-2016/) is confirmatory for tubal/ovarian high-grade serous 
274 carcinoma. In case of diagnostic uncertainty, in order to preserve tissue, the case 
275 should be sent to a cancer centre for review before further tissue is used for 
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276 immunohistochemistry. The second block should have an H&E stain to confirm 
277 presence of malignancy. This is the tissue that needs to be sent to the nominated 
278 pathologist/s. In resection specimens, the reporting pathologist should send one 
279 block of primary or metastatic carcinoma containing maximum viable and well-fixed 
280 tumour with its H&E-stained slide to the a designated pathologist.  Cellblock from 
281 cytology received with suspicion of ovarian cancer should be sent to pathologist if 
282 confirmatory of tubal/ovarian high-grade serous carcinoma.  
283 Pathology teams and clinical teams should jointly establish pathways for 
284 communication of requests for tumour testing. This communication should clearly 
285 document patient consent for testing. The nominated pathologist should mark tumour 
286 areas on H&E slide and estimate tumour volume. The tissue (as required by the 
287 genomic laboratory hub), marked slide and completed form are sent to the genomic 
288 laboratory hub. This should be recorded securely and, where possible, this record 
289 should be accessible to the clinical team. When result received, the result should be 
290 added to the initial pathology report as a supplementary and/or upload report on 
291 electronic patient record. 
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292 Genomic Laboratory Hub considerations 
293 The NHS Genomic Laboratory Hub network has limited capacity to undertake 
294 assessment of pathology samples for adequacy for somatic BRCA analysis from 
295 ovarian cancer patients. Their specialist expertise is the analysis of nucleic acids. It 
296 is the primary responsibility of the pathology laboratory holding the tissue sample to 
297 undertake an assessment of the adequacy of tissue samples for tumour BRCA 
298 analysis. This should include an assessment of the neoplastic cell content of the 
299 sample. It is recommended that the neoplastic cell content of samples should be at 
300 least twice the limit of detection of the assay used. For next generation sequencing 
301 based assays, the typical minimum neoplastic cell content for reliable detection of 
302 pathogenic variants is 20%. Formalin fixed paraffin embedded samples with less 
303 than 20% neoplastic cell content and regions of higher neoplastic cell content may 
304 be ‘rescued’ by macrodissection in the genomic laboratory. Macrodissection by the 
305 referring pathologist should, therefore, be considered for any samples where the 
306 neoplastic cell content is less than the minimum recommended by the genomics 
307 laboratory. A clearly marked H&E-stained guide slide with areas of neoplasia ringed 
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308 using an indelible marker should be sent along with unstained slide mounted 
309 sections. The H&E guide slide should be derived from a serial section next to the 
310 sections sent for genomic analysis. Tissue morphology can change as successive 
311 sections are cut from the block and a neighbouring section mitigates against 
312 macrodissecting an inappropriate region of the tissue section. 
313 Genomic target test turnaround times for genomic laboratory hubs in England are set 
314 by National Health Service England.  The key turnaround times appropriate for 
315 ovarian cancer are 21 calendar days for tumour BRCA analysis and 42 calendar 
316 days for germline BRCA analysis. Genomic laboratories are expected to meet these 
317 in at least 90% of the cases.
318 Consent issues
319 With the roll-out of the NHS Genomic Medicine Service, patients across England 
320 gain equity of access to genomic testing for the first time, including whole genome 
321 sequencing for certain rare diseases and cancers. Healthcare professionals will need 
322 to be equipped to facilitate patient consent to these tests, and provide the 
323 information and support required.
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324 To support this, the Genomics Education Programme has developed a competency 
325 framework that identifies eight areas of proficiency to facilitate and consent patients 
326 to genomic tests. (https://www.genomicseducation.hee.nhs.uk/consent-a-competency-
327 framework/).  It is intended as a cross-professional guide for best practice and has 
328 been designed around four categories of healthcare professionals based on their 
329 training and experience with genomics. The competency framework can be used by 
330 individual healthcare professionals as a guide to help them identify their learning 
331 needs. For educators, the framework provides a mechanism to recognise the training 
332 needs of health professional groups, and to structure training so that consent 
333 conversations about genomic testing can be delivered consistently across different 
334 specialties. In addition, the competencies can be used to evaluate how consent is 
335 being facilitated in different practice areas to enhance the delivery of genomic 
336 medicine.
337 Crucially, with the new framework, consent is rightly seen as a process whereby an 
338 ’offer’ is made, adequate information provided and discussions to enable informed 
339 choice by patients are provided. Until the ‘patient choice’ forms are readily available 
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340 in the UK (as detailed in the Genomics education programme), the current consent 
341 forms can be used and adapted to indicate if a patient has provided consent for 
342 somatic/germline/or combination (parallel) testing.  It must be recorded in the patient 
343 notes that the discussion about opting to have a BRCA test has taken place over 
344 different points in the diagnostic/treatment work up. The consenting process should 
345 comply with General Medical Council standards. (https://www.gmc-uk.org/ethical-
346 guidance/ethical-guidance-for-doctors/consent)  
347 In all cases, high quality, culturally appropriate information must be provided to 
348 patients so they can make an informed decision. Please see Appendix 2-4 for 
349 template letters.
350 Recording of BRCA status and multidisciplinary team meeting outputs
351 Consistency of terminology is important to avoid confusion. For instance, use of the 
352 term “BRCA positive” should be avoided as it can be interpreted to mean the 
353 diametric opposites of the positive presence of a mutation or the positive presence of 
354 protein. To avoid confusion the following terms should therefore be used: germline 
355 variant – a variant detected in the blood sample vs. tumour variant – a variant 
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356 detected in the tumour. Importantly, without reference to the blood sample, a tumour 
357 variant could be either germline or somatic. Somatic variant – a pathogenic variant 
358 detected in the tumour sample which is not present in the blood sample. To define a 
359 somatic variant therefore requires that both a blood and a tumour sample have been 
360 analysed. 
361 For ease of recording a common notation is to use a prefix to define the type of 
362 variant described and a suffix to describe the result. Using these notations, g, t, s are 
363 used to describe germline, tumour and somatic, respectively. Additionally, m, vus & 
364 wt are used to describe pathogenic or likely-pathogenic variant (mutation), variant of 
365 unknown significance and wild type respectively. For example, gBRCA1m would 
366 describe a germline variant (pathogenic or likely-pathogenic variant) of BRCA1, in 
367 contrast to sBRCA2wt which would describe a somatic wild type (no pathogenic 
368 variant) BRCA2. For more information on classes of variant. Table 2
369 Patient perspectives
370 Conversations with gynaecological cancer charities have highlighted issues of 
371 concern and importance for patients that need to be considered when implementing 
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372 BRCA testing.  Critically, patients should feel reassured that the timing of BRCA 
373 testing is their decision as patients may feel ready to undergo testing at different 
374 points in their journey. High quality, culturally appropriate information is vital to this. 
375 Table 3
376 Conclusions
377 Germline testing has significant implications for patients, in terms of therapy choices, 
378 but also for their families in terms of risk management and the development of 
379 additional tumours. Tumour BRCA testing identifies an additional subgroup of 
380 women who have benefit from PARP inhibitors. Recommendations for testing are 
381 summarised in Table 4. It remains of critical importance to stratify patients and 
382 identify those who do not have a BRCA (germline/somatic) pathogenic variant as this 
383 group of women are least likely to benefit from PARP inhibitors and should therefore 
384 be considered for studies of novel therapies/combinations going forward. 
385 Additionally, family members who have a pathogenic/likely pathogenic variant can 
386 opt for a range of interventions such as reproductive choices, prenatal genetic 
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387 diagnosis, planning a family, risk reduction surgery, screening or chemoprevention to 
388 minimize their ovarian cancer and breast cancer risk. 
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